Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are:
- To evaluate the safety of Nyxol in pediatric subjects
- To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically induced
mydriasis in pediatric subjects The Sponsor intends to use this study to evaluate Nyxol
in pediatric subjects aged 3 to 11 for the indication "the treatment of
pharmacologically induced mydriasis produced by adrenergic (phenylephrine) or
parasympatholytic (tropicamide) agents, or a combination thereof."